Please use this identifier to cite or link to this item: https://hdl.handle.net/10137/7188
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSchully KLen
dc.contributor.authorYoung CCen
dc.contributor.authorMayo MJen
dc.contributor.authorConnolly ALen
dc.contributor.authorRigas Ven
dc.contributor.authorSpall Aen
dc.contributor.authorChan AAen
dc.contributor.authorSalvador MGen
dc.contributor.authorLawler JVen
dc.contributor.authorOpdyke JAen
dc.contributor.authorClark DVen
dc.contributor.authorCurrie BJen
dc.date2018en
dc.date.accessioned2018-11-12T04:45:55Zen
dc.date.available2018-11-12T04:45:55Zen
dc.date.issued2018-10-31en
dc.identifier.citationClinical infectious diseases : an official publication of the Infectious Diseases Society of America 2018-10-31en
dc.identifier.urihttps://hdl.handle.net/10137/7188en
dc.description.abstractInfection with the gram-negative bacterium Burkholderia pseudomallei can result in melioidosis, a life-threatening disease that can be difficult to diagnose. Culture remains the gold standard for diagnosis but requires laboratory resources not available in many endemic regions. A lateral flow immunoassay has shown promise for POC diagnostics but suffers from low sensitivity when used on blood samples. PCR also has low sensitivity on blood, attributed to the low bacterial numbers in blood observed in melioidosis patients, even when bacteraemic. A prototype i-STAT cartridge was developed to utilize the monoclonal antibody specific for the capsule of pathogenic Burkholderia species employed on the LFI. The resulting POC assay was evaluated on 414 clinical specimens from Darwin, Australia and Cambodia. The i-STAT assay accurately distinguished Australian blood culture positive melioidosis patients from Australian patients hospitalized with other infections (AUC = 0.91, 95% CI 0.817 - 1.0). We derived an assay cutoff with 76% sensitivity and 94% specificity that correctly classified 88% (n=74) of the Australian patients. Interestingly, only 46% (6/13) of the culture-positive melioidosis patients in Cambodia were classified correctly. Of great importance however, the assay detected capsule from blood samples for 32% of blood culture negative melioidosis patients in both cohorts and previously undiagnosed melioidosis patients in Cambodia. In addition the assay showed high sensitivity and specificity for urine, pus and sputum. Diagnostic tools that are not dependent upon the growth kinetics or the levels of bacteremia of B. pseudomallei represent the next-generation of diagnostics and must be pursued further.en
dc.language.isoengen
dc.titleNext Generation Diagnostics for Melioidosis: Evaluation of a Prototype i-STAT Cartridge to Detect Burkholderia pseudomallei Biomarkers.en
dc.typeJournal Articleen
dc.identifier.journaltitleClinical infectious diseases : an official publication of the Infectious Diseases Society of Americaen
dc.identifier.doi10.1093/cid/ciy929en
dc.identifier.pubmedidhttps://www.ezpdhcs.nt.gov.au/login?url=https://www.ncbi.nlm.nih.gov/pubmed/30403768en
dc.identifier.affiliationAustere environments Consortium for Enhanced Sepsis Outcomes (ACESO), Biological Defense Research Directorate, Naval Medical Research Center-Frederick, Ft. Detrick, MD, USA..en
dc.identifier.affiliationThe Johns Hopkins University Applied Physics Laboratory, Laurel, MD, USA..en
dc.identifier.affiliationGlobal and Tropical Health Division, Menzies School of Health Research, Darwin, Australia..en
dc.identifier.affiliationThe Johns Hopkins University Applied Physics Laboratory, Laurel, MD, USA..en
dc.identifier.affiliationGlobal and Tropical Health Division, Menzies School of Health Research, Darwin, Australia..en
dc.identifier.affiliationAustere environments Consortium for Enhanced Sepsis Outcomes (ACESO), Biological Defense Research Directorate, Naval Medical Research Center-Frederick, Ft. Detrick, MD, USA..en
dc.identifier.affiliationAustere environments Consortium for Enhanced Sepsis Outcomes (ACESO), Biological Defense Research Directorate, Naval Medical Research Center-Frederick, Ft. Detrick, MD, USA..en
dc.identifier.affiliationAustere environments Consortium for Enhanced Sepsis Outcomes (ACESO), Biological Defense Research Directorate, Naval Medical Research Center-Frederick, Ft. Detrick, MD, USA..en
dc.identifier.affiliationAustere environments Consortium for Enhanced Sepsis Outcomes (ACESO), Biological Defense Research Directorate, Naval Medical Research Center-Frederick, Ft. Detrick, MD, USA..en
dc.identifier.affiliationJoint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, Medical Countermeasure Systems, Ft. Detrick, MD, USA..en
dc.identifier.affiliationAustere environments Consortium for Enhanced Sepsis Outcomes (ACESO), Biological Defense Research Directorate, Naval Medical Research Center-Frederick, Ft. Detrick, MD, USA..en
dc.identifier.affiliationGlobal and Tropical Health Division, Menzies School of Health Research, Darwin, Australia.. Department of Infectious Diseases and Northern Territory Medical Program, Royal Darwin Hospital, Darwin, Australia..en
Appears in Collections:(a) NT Health Research Collection

Files in This Item:
There are no files associated with this item.


Items in ePublications are protected by copyright, with all rights reserved, unless otherwise indicated.

Google Media

Google ScholarTM

Who's citing